WO2000053569A1 - Method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol and intermediates useful in such preparation - Google Patents

Method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol and intermediates useful in such preparation Download PDF

Info

Publication number
WO2000053569A1
WO2000053569A1 PCT/CN2000/000046 CN0000046W WO0053569A1 WO 2000053569 A1 WO2000053569 A1 WO 2000053569A1 CN 0000046 W CN0000046 W CN 0000046W WO 0053569 A1 WO0053569 A1 WO 0053569A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
compound
product
vii
alkylphenyl
Prior art date
Application number
PCT/CN2000/000046
Other languages
French (fr)
Chinese (zh)
Inventor
Dali Yin
Donghui Wang
Yonghua Zhang
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
Institute Of Materia Medica, Chinese Academy Of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd., Institute Of Materia Medica, Chinese Academy Of Medical Sciences filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
Priority to AU31426/00A priority Critical patent/AU3142600A/en
Publication of WO2000053569A1 publication Critical patent/WO2000053569A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Definitions

  • the present invention relates to a method for preparing 2- [2- (4-alkylphenyl) -ethyl] -2-amino-propanediol, and more particularly, to a method for preparing a compound of the following structural formula (I), and in the preparation An intermediate produced in the process. Background technique
  • FTY-720 The compound of the following structural formula is abbreviated as FTY-720, and its chemical name is 2-amino-2- [2- (4-octylphenyl) ethyl] -1,3-propanediol hydrochloride.
  • This compound was originally disclosed in PCT / JP93 / 01515, has immunosuppressive activity, and is expected to become a new immunosuppressant for clinical use (see PCT / JP93 / 01515).
  • the method disclosed in the above PCT application uses protected phenylethanol as a starting material, and the entire synthetic route undergoes 10 steps of reaction.
  • the main disadvantage of this method is that, due to the instability of the phenylethanol acetate compound, the Fnedle-Crafts acylation reaction of phenylethanol acetate and octanoyl chloride is low, and the total yield is lower than this. Low and not suitable for large-scale preparation. Therefore, the object of the present invention is to provide an improved method for preparing fluorenylphenylethylaminopropanediol, which overcomes the defects of the prior art, and has the advantages of low reaction cost and high yield.
  • the present invention includes a method for preparing 2- [2- (4-fluorenylphenyl) -ethyl] -2-amino-propanediol of the following general formula (I):
  • R is a C1-10 alkyl group
  • the method includes the following steps:
  • Fluorenylbenzene (II) reacts with acetyl chloride in the presence of Lewis acid to form p-fluorenylacetophenone (III);
  • the product (III) is formed into p-alkyl ⁇ -haloacetophenone (IV) by conventional methods in the presence of a small amount of Lewis acid;
  • the present invention includes an intermediate product obtained in the above preparation method
  • the preparation method of the present invention uses fluorenylbenzene II as a starting material, wherein the fluorenyl group R is a linear or branched fluorenyl group of C1-10, preferably n-octyl.
  • the Fnedel-Crafts reaction of II with acetyl chloride is carried out under the catalysis of a Lewis acid, preferably A1C1 3 , to produce the product (III).
  • III has sufficient purity and can be used in the following reactions without purification.
  • Compound IV can be prepared by ⁇ -halogenation of III, and the reaction is performed according to a conventional method known to those skilled in the art, using a small amount of Lew 1S acid, preferably A1 (3 ⁇ 4) as a catalyst for the reaction.
  • X is Br or Cl, and Br is preferred.
  • Condensation of IV and V under basic conditions to obtain the key intermediate VI of the present invention, as described above; is (: 1 to 4 acyl, preferably acetyl; but (1 to 4 alkyl, preferably Methyl and ethyl.
  • Common bases such as sodium ethoxide, sodium methoxide, sodium hydride, potassium tert-butoxide, etc., of which sodium ethoxide and sodium methoxide are preferred.
  • the molar ratio of reactants IV to V is 1: 1 to 1: 2.
  • the ratio of Na to IV is 1-1.5: 1.
  • the reducing agents used are aluminum or boron rehydrides and their derivatives, preferably LiAlH 4 , NaBH 4 , KB ⁇ n LiBH 4 , and most preferably NaBH 4 .
  • the solvent used in the reaction in this step is a common solvent when using a dehydrogenated compound, such as water, methanol or ethanol. It is obvious to those skilled in the art that the reaction of this step also requires the participation of a buffer of borate or phosphate.
  • the intermediate VII is hydrolyzed to obtain yet another important intermediate VIII of the present invention, wherein R is the same as the aforementioned ⁇ .
  • This step can be performed with a strong base such as NaOH, KOH, LiOH or a strong acid such as HC1, ⁇ 04 in water or an alcohol (eg, methanol, ethanol).
  • target compound I can also be prepared by first hydrolyzing the compound VII and then hydrolyzing the N-acyl group.
  • the product VI can also be subjected to hydrogenolysis as described above to form 2-amido-2- [2-p-alkylphenylmonoethyl] malonate, whose structural formula is as follows , -. Wherein R n R 3 is as described above, and then the ester is reduced and hydrolyzed as described above to finally obtain compound I.
  • Compound I can further form salts with acids.
  • the acid may be HC1, H 2 S0 4 ,
  • the total yield is about 5% (based on the salt-forming material).
  • the method according to the present invention not only has the characteristics of short synthetic route and simple operation, but also has a relatively high yield in each step. High, the total yield can reach about 20-25% (based on the material after salt formation). Therefore, the method of the present invention is a more economical, faster and more effective method for preparing 2- [2- (4-fluorenylphenyl) -ethyl] -2-amino-propanediol.
  • Example 1 The present invention will be further described by examples below, but these examples are only used to illustrate the present invention and not to limit the scope of the present invention.
  • Example 1
  • the 2-acetamido-2- [2- (4-octylphenyl) -2-oxo-ethyl] -1,3-dimalonate (1.76 g, 4.0 mmol) was dissolved in 30 ml of methanol, and 100 mg of 10% Pd-C and HC10 4 (0.8 g, 5.5 mmol) were added.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to a method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol compounds of general formula (I), wherein R is C1-10 alkyl, preferably n-octyl, which comprises the following steps: reacting alkylbenzene (II) with acetyl chloride in the presence of Lewis acid; preparing p-alkyl α-halophenylethyl ketone (IV) according to a conventional method in the presence of a small amount of Lewis acid; condensing the obtained compound (IV) with 2-acylamino-malonate to give 2-acylamino-2-[2-p-alkylphenyl-2-oxo-ethyl]-malonate (VI) in the presence of a base; reducing product (VI) to 2-acylamino-2-[2-p-alkylphenyl-2-hydroxy-ethyl]-propanediol (VII); then hydrolyzing and hydrogenating compound (VII) to form compound (I). This invention also relates to the intermediates involved in the above method.

Description

Figure imgf000003_0001
明 书 制备 2-[2-(4-垸基苯基) -乙基】-2-氨基-丙二醇的方法
Figure imgf000003_0001
Method for preparing 2- [2- (4-fluorenylphenyl) -ethyl] -2-amino-propanediol by clear book
以及其中制得的中间产物 发明领域  FIELD OF THE INVENTION Field of the Invention
本发明涉及 2-[2-(4-烷基苯基) -乙基 ]-2-氨基-丙二醇的制备方法, 更 具体而言是涉及以下结构式 (I) 化合物的制备方法, 以及在该制备方 法中制得的中间产物。
Figure imgf000003_0002
背景技术
The present invention relates to a method for preparing 2- [2- (4-alkylphenyl) -ethyl] -2-amino-propanediol, and more particularly, to a method for preparing a compound of the following structural formula (I), and in the preparation An intermediate produced in the process.
Figure imgf000003_0002
Background technique
以下结构式的化合物简称为 FTY-720, 其化学名称为 2-氨基 -2-[2- (4-辛基苯基)乙基] -1,3-丙二醇盐酸盐。
Figure imgf000003_0003
该化合物最初在 PCT/JP93/01515中公开, 具有免疫抑制活性, 有 望成为新的免疫抑制剂用于临床 (参见 PCT/JP93/01515 ) 。
The compound of the following structural formula is abbreviated as FTY-720, and its chemical name is 2-amino-2- [2- (4-octylphenyl) ethyl] -1,3-propanediol hydrochloride.
Figure imgf000003_0003
This compound was originally disclosed in PCT / JP93 / 01515, has immunosuppressive activity, and is expected to become a new immunosuppressant for clinical use (see PCT / JP93 / 01515).
上述 PCT申请中公开的方法是以保护的苯乙醇为起始原料, 整个 合成路线共经历 10步反应。 该方法的主要不足之处在于, 由于苯乙醇 乙酸酯化合物本身的不稳定性, 苯乙醇乙酸酯与辛酰氯的 Fnedle-Crafts 酰化反应收率低, 并由此导致其总收率较低, 不适合大量制备。 W 因此,本发明的目的是提供一种经改进的制备垸基苯基乙基氨基丙 _ 二醇的方法, 该方法克服了现有技术的缺陷, 具有反应成本低、 收率高 的优点。 The method disclosed in the above PCT application uses protected phenylethanol as a starting material, and the entire synthetic route undergoes 10 steps of reaction. The main disadvantage of this method is that, due to the instability of the phenylethanol acetate compound, the Fnedle-Crafts acylation reaction of phenylethanol acetate and octanoyl chloride is low, and the total yield is lower than this. Low and not suitable for large-scale preparation. Therefore, the object of the present invention is to provide an improved method for preparing fluorenylphenylethylaminopropanediol, which overcomes the defects of the prior art, and has the advantages of low reaction cost and high yield.
本发明的再一个目的是提供在本发明方法中制得的中间产物。 发明公开  It is a further object of the present invention to provide an intermediate product obtained in the method of the present invention. Invention Disclosure
根据一个方面,本发明包括制备以下通式(I)之 2-[2-(4-垸基苯基) - 乙基] -2-氨基-丙二醇的方法:
Figure imgf000004_0001
式中: R为 C1一 10的烷基;
According to one aspect, the present invention includes a method for preparing 2- [2- (4-fluorenylphenyl) -ethyl] -2-amino-propanediol of the following general formula (I):
Figure imgf000004_0001
In the formula: R is a C1-10 alkyl group;
所述方法包括以下步骤:  The method includes the following steps:
1、垸基苯(II)与乙酰氯在 Lewis酸存在下反应, 生成对垸基苯乙 酮 (III) ;  1. Fluorenylbenzene (II) reacts with acetyl chloride in the presence of Lewis acid to form p-fluorenylacetophenone (III);
2、 产物 (III) 在少量 Lewis酸存在下按常规方法形成对烷基 α— 卤代苯乙酮 (IV) ;  2. The product (III) is formed into p-alkyl α-haloacetophenone (IV) by conventional methods in the presence of a small amount of Lewis acid;
3、 产物 (IV)与 2—酰胺基丙二酸酯(V)在碱性条件下缩合形成 2—酰胺基—2— [2—对垸基苯基— 2—氧一乙基]丙二酸酯 (VI) ;  3. The product (IV) is condensed with 2-amidomalonate (V) under basic conditions to form 2-amido-2— [2-p-fluorenylphenyl—2-oxoethyl] malon Acid ester (VI);
4、产物(VI)还原为 2—酰胺基一 2— [2—对烷基苯基一2—羟基一 乙基]丙二醇 (VII) ;  4. The product (VI) is reduced to 2-amido- 2- [2-p-alkylphenyl 2-hydroxy-ethyl] propanediol (VII);
5、 产物 (VII) 经水解形成 2—氨基一 2— [2—对烷基苯基一 2—羟 基一乙基]丙二醇 (VIII) ; 然后  5. The product (VII) is hydrolyzed to form 2-amino-1 2- [2-p-alkylphenyl-2-hydroxylethyl] propanediol (VIII); then
6、 产物 (VIII) 经氢解形成化合物 (I) 。 根据另一个方面, 本发明包括上述制备方法中制得的中间产物 6. The product (VIII) is hydrolyzed to form the compound (I). According to another aspect, the present invention includes an intermediate product obtained in the above preparation method
(VI) 、 (VII) 和 (VIII) 。  (VI), (VII) and (VIII).
发明的详细描述 Detailed description of the invention
根据本发明的制备 2-[2-(4-烷基苯基 乙基] -2-氨基-丙二醇的方法 可简单表示如下:  The method for preparing 2- [2- (4-alkylphenylethyl] -2-amino-propanediol according to the present invention can be simply expressed as follows:
Figure imgf000005_0001
Figure imgf000005_0001
OH CH2OH OH CH 2 OH
还原 Ri cH_ CH2-Cr NHR2 vn Reduction Ri cH _ CH 2-Cr NHR 2 vn
CH2OH 水解CH 2 OH hydrolysis
Figure imgf000005_0002
Figure imgf000005_0003
Figure imgf000005_0002
Figure imgf000005_0003
本发明的制备方法是以垸基苯 II为起始原料,其中的垸基 R,为 C1 —10的直链或支链垸基, 优选为正辛基。 II与乙酰氯的 Fnedel-Crafts 反应在 Lewis酸、 优选 A1C13催化下进行, 生成产物 (III) 。 III具有足 够的纯度, 不需精制即可用于以下的反应。 The preparation method of the present invention uses fluorenylbenzene II as a starting material, wherein the fluorenyl group R is a linear or branched fluorenyl group of C1-10, preferably n-octyl. The Fnedel-Crafts reaction of II with acetyl chloride is carried out under the catalysis of a Lewis acid, preferably A1C1 3 , to produce the product (III). III has sufficient purity and can be used in the following reactions without purification.
化合物 IV可通过 III的 α —卤化来制备,反应按本领域技术人员已 知的常规方法进行, 用少量 Lew1S酸、 优选 Α1(¾作为反应的催化剂。 X为 Br或 Cl, 其中优选 Br。 一Compound IV can be prepared by α-halogenation of III, and the reaction is performed according to a conventional method known to those skilled in the art, using a small amount of Lew 1S acid, preferably A1 (¾) as a catalyst for the reaction. X is Br or Cl, and Br is preferred. One
IV与 V在碱性条件下縮合得到本发明的关键中间体 VI, 其中 如以上所述; 是(:1一 4的酰基, 优选为乙酰基; 而 是( 1一4的烷 基, 优选为甲基和乙基。 常用的碱如乙醇钠、 甲醇钠、 氢化钠和叔丁醇 钾等, 其中优选乙醇钠和甲醇钠。 反应物 IV与 V的摩尔比为 1 : 1 - 1: 2, Na与 IV的比例为 1— 1.5 : 1。 Condensation of IV and V under basic conditions to obtain the key intermediate VI of the present invention, as described above; is (: 1 to 4 acyl, preferably acetyl; but (1 to 4 alkyl, preferably Methyl and ethyl. Common bases such as sodium ethoxide, sodium methoxide, sodium hydride, potassium tert-butoxide, etc., of which sodium ethoxide and sodium methoxide are preferred. The molar ratio of reactants IV to V is 1: 1 to 1: 2. The ratio of Na to IV is 1-1.5: 1.
式 VI化合物经复氢化合物还原制得本发明的另一个关键中间体  Reduction of a compound of formula VI with a dehydrogenated compound yields another key intermediate of the present invention
VII, 其中 和1 2如以上所述。所用的还原剂为铝或硼的复氢化物及其 衍生物, 优选为 LiAlH4、 NaBH4、 KB¾^n LiBH4, 最优选为 NaBH4。 该步反应中所用的溶剂为使用复氢化合物时的常用溶剂, 例如水、 甲醇 或乙醇。该步骤的反应还需硼酸盐或磷酸盐的缓冲液参与, 这对本领域 技术人员是显而易见的。 VII, and 12 which, as described above. The reducing agents used are aluminum or boron rehydrides and their derivatives, preferably LiAlH 4 , NaBH 4 , KB ^ n LiBH 4 , and most preferably NaBH 4 . The solvent used in the reaction in this step is a common solvent when using a dehydrogenated compound, such as water, methanol or ethanol. It is obvious to those skilled in the art that the reaction of this step also requires the participation of a buffer of borate or phosphate.
中间体 VII水解得到本发明的再一个重要中间体 VIII,其中 R与上 述1^相同。 该步骤中可用强碱如 NaOH、 KOH、 LiOH或强酸如 HC1、 ≤〇4在水或醇 (例如甲醇、 乙醇) 中进行。 The intermediate VII is hydrolyzed to obtain yet another important intermediate VIII of the present invention, wherein R is the same as the aforementioned ^. This step can be performed with a strong base such as NaOH, KOH, LiOH or a strong acid such as HC1, ≦ 04 in water or an alcohol (eg, methanol, ethanol).
VIII在酸性条件下加氢氢解可直接得到目的化合物 I, 其中可使用 本领域技术人员已知的催化量的氢解催化剂, 例如 Pd— C, 而氢压为 1 —5 kg/cm2 o VIII Hydrogenolysis under acidic conditions can directly obtain the target compound I, in which a catalytic amount of a hydrogenolysis catalyst known to those skilled in the art, such as Pd-C, can be used, and the hydrogen pressure is 1-5 kg / cm 2 o
对本领域技术人员显而易见的是,也可以将化合物 VII先氢解然后 水解 N—酰基, 由此制得目的化合物 I。  It is obvious to a person skilled in the art that the target compound I can also be prepared by first hydrolyzing the compound VII and then hydrolyzing the N-acyl group.
根据本发明的另一种实施方案, 产物 VI也可如以上所述进行氢 解, 形成 2—酰胺基一 2— [2—对烷基苯基一乙基]丙二酸酯, 其结构式 如下,
Figure imgf000006_0001
- . 式中 R n R3如上所述, 然后该酯再如以上所述进行还原和水解, 一 最终制得化合物 I。
According to another embodiment of the present invention, the product VI can also be subjected to hydrogenolysis as described above to form 2-amido-2- [2-p-alkylphenylmonoethyl] malonate, whose structural formula is as follows ,
Figure imgf000006_0001
-. Wherein R n R 3 is as described above, and then the ester is reduced and hydrolyzed as described above to finally obtain compound I.
化合物 I还可进一步与酸形成盐。 所述酸可以是 HC1、 H2S04Compound I can further form salts with acids. The acid may be HC1, H 2 S0 4 ,
HC104、 HBr、 HO Ac等。 HC10 4 , HBr, HO Ac, etc.
与现有技术的方法相比, 其总收率约为 5 % (以成盐后的物质计), 根据本发明的方法不仅具有合成路线短、操作简便的特点, 而且各步反 应收率较高, 总收率可达到约 20— 25 % (以成盐后的物质计) 。 因此, 本发明的方法是一种更经济、更快捷、更有效的制备 2-[2-(4-垸基苯基) - 乙基] -2-氨基-丙二醇的方法。  Compared with the prior art method, the total yield is about 5% (based on the salt-forming material). The method according to the present invention not only has the characteristics of short synthetic route and simple operation, but also has a relatively high yield in each step. High, the total yield can reach about 20-25% (based on the material after salt formation). Therefore, the method of the present invention is a more economical, faster and more effective method for preparing 2- [2- (4-fluorenylphenyl) -ethyl] -2-amino-propanediol.
以下将通过实施例进一步描述本发明,但这些实施例仅是用于说明 本发明, 而不是对本发明范围的限制。 实施例 1  The present invention will be further described by examples below, but these examples are only used to illustrate the present invention and not to limit the scope of the present invention. Example 1
4-辛基-苯乙酮的制备  Preparation of 4-octyl-acetophenone
将辛基苯(9.1 g, 48 mmol)和乙酰氯(4.7 g, 60 mmol)的混合物冰 浴冷却, 搅拌下在 1小时内分次加入无水 A1C13 ( 8.9 g, 67 mmol ) 。 继 续搅拌 1小时, 倾入冰水中, 乙酸乙酯提取。有机层分别用 1N HC1洗, 水洗至中性, 无水硫酸钠干燥, 浓缩得 9.2g油状物。 A mixture of octylbenzene (9.1 g, 48 mmol) and acetyl chloride (4.7 g, 60 mmol) was cooled in an ice bath, and anhydrous A1C1 3 (8.9 g, 67 mmol) was added portionwise over 1 hour with stirring. Stirring was continued for 1 hour, poured into ice water, and extracted with ethyl acetate. The organic layer was washed with 1N HC1, washed with water to neutrality, dried over anhydrous sodium sulfate, and concentrated to obtain 9.2 g of an oil.
'HNMR (300Mhz, CDC13) δ 7.88 (d, J = 8.1Hz, 2H ), 7,26 (d, J - 8.1Hz, 2H ), 2.65 ( t, J = 7.2Hz, 2H ), 2.60 ( s, 3H ), 1.62 ( m, 2H ), 1.26 ( m, 10H ), 0.87 ( t, J = 6.3Hz, 3H ) 实施例 2 'HNMR (300Mhz, CDC1 3 ) δ 7.88 (d, J = 8.1Hz, 2H), 7,26 (d, J-8.1Hz, 2H), 2.65 (t, J = 7.2Hz, 2H), 2.60 (s , 3H), 1.62 (m, 2H), 1.26 (m, 10H), 0.87 (t, J = 6.3Hz, 3H) Example 2
4-辛基 - a -溴代苯乙酮的制备  Preparation of 4-octyl-a-bromoacetophenone
将 4-辛基-苯乙酮 (4.2 g, 18 mmol ) 溶于 5 ml乙醚中, 冰浴冷却下 加入 A1C13 (50 mg) 搅拌下, 在 1小时内滴加 Br2 (2.9 g, 18 mmol) , 继续搅拌 30分钟, 减压浓缩, 所得固体分别用冰水洗, 冰冷的 95 %乙 醇洗, 减压干燥得 4.8 g 4-辛基 - α -溴代苯乙酮。 实施例 3 4-octyl-acetophenone (4.2 g, 18 mmol) was dissolved in 5 ml of ether, and the solution was cooled in an ice bath. Add A1C1 3 (50 mg) under stirring, add Br 2 (2.9 g, 18 mmol) dropwise within 1 hour, continue stirring for 30 minutes, and concentrate under reduced pressure. The resulting solids were washed with ice water and ice-cold 95% ethanol. Pressure drying gave 4.8 g of 4-octyl-α-bromoacetophenone. Example 3
2-乙酰胺基 -2-[2-(4-辛基苯基) -2-氧-乙基】 -1, 3-丙二酸二乙酯  2-acetamido-2- [2- (4-octylphenyl) -2-oxo-ethyl] -1,3-dimalonate
将 Na (0.4 g, 17.2 mmol)溶于 16 ml乙醇中, 加入乙酰胺基丙二酸 二乙酯 (4.7 g, 21.6 mmol) , 冰浴冷却下, 40分钟内滴加 4-辛基 - α -溴 代苯乙酮 (4.8 g, 15.4 mmol) 的无水乙醚溶液。 0。C搅拌 2小时, 减压 浓缩, 残余物以乙酸乙酯提取, 水洗至中性, 无水硫酸钠干燥, 浓缩, 粗品经柱层析分离(石油醚 /乙酸乙酯 =3 : 1 )得 6.2 g油状物, 收率 95 % (自辛基苯计) 。  Dissolve Na (0.4 g, 17.2 mmol) in 16 ml of ethanol, add diethyl acetaminomalonate (4.7 g, 21.6 mmol), and add 4-octyl-α dropwise over 40 minutes under ice cooling. -Bromoacetophenone (4.8 g, 15.4 mmol) in anhydrous ether. 0. C was stirred for 2 hours, and concentrated under reduced pressure. The residue was extracted with ethyl acetate, washed with water to neutrality, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (petroleum ether / ethyl acetate = 3: 1) to obtain 6.2. g oil, yield 95% (based on octylbenzene).
!HNMR (300Mhz, CDC13) δ 7.86 (d, J = 8.1Hz, 2H ), 7.26 ( d, J= 8.1Hz, 2H ), 7.10 ( s, 1H ), 4.35-4.20 ( m, 6H ), 2.64 ( t, J= 7.8Hz, 2H ), 1.93 ( s, 3H ), 1.60 (m, 2H ), 1.40-1.18 ( m, 16H ), 0.86 ( t, J = 6.6Hz, 3H ); EI-MS m/z 448 (M+l), 217 实施例 4 (还原) ! HNMR (300Mhz, CDC1 3 ) δ 7.86 (d, J = 8.1Hz, 2H), 7.26 (d, J = 8.1Hz, 2H), 7.10 (s, 1H), 4.35-4.20 (m, 6H), 2.64 (t, J = 7.8Hz, 2H), 1.93 (s, 3H), 1.60 (m, 2H), 1.40-1.18 (m, 16H), 0.86 (t, J = 6.6Hz, 3H); EI-MS m / z 448 (M + l), 217 Example 4 (reduction)
2-乙酰胺基 -2-[2-(4-辛基苯基) -2-羟基 -乙基 H,3-丙二醇  2-acetamido-2- [2- (4-octylphenyl) -2-hydroxy-ethyl H, 3-propanediol
将 2-乙酰胺基 -2-[2- (对 -辛基苯基) -2-氧-乙基] -1, 3-丙二酸二乙酯 ( 1.68 g, 3.8 mmol ) 溶于 30 ml 95 %乙醇中, 加入 Κ2ΗΡ04·3Η20水溶 液 ( 6.84 g, 30 mmol),然后加入 NaBH4的 NaOH水溶液 (0.74 g NaBH, / 5 ml H2O / 0.5 ml 10% NaOH), 室温下搅拌 6小时后减压抽去乙醇, 乙酸乙酯提取,有机层分别用 1N HC1,饱和 NaHC03,饱和 NaCl洗涤, 无水 NaS04干燥, 浓缩得白色固体 1.29 g, 乙酸乙酯重结晶得 940 mg, 收率 68%。 Dissolve 2-acetamido-2- [2- (p-octylphenyl) -2-oxo-ethyl] -1,3-dimalonate (1.68 g, 3.8 mmol) in 30 ml In 95% ethanol, add K 2 ΗΡ0 4 · 3Η 2 0 aqueous solution (6.84 g, 30 mmol), and then add NaBH 4 NaOH aqueous solution (0.74 g NaBH, / 5 ml H 2 O / 0.5 ml 10% NaOH), room temperature After stirring for 6 hours under reduced pressure, ethanol was removed under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with 1N HC1, saturated NaHC0 3 and saturated NaCl, dried over anhydrous NaS0 4 and concentrated to give 1.29 g of white solid. 940 mg, The yield was 68%.
"HNMR (300Mhz, DMSO) δ 7.18 ( d, J = 7.8Hz, 2H ), 7.09 (d, J = 7.8Hz, 2H ), 4.67 ( d, J= 9.6Hz, 1H ), 3.65-3.45 ( m, 4H ), 2.60-2.40 ( m, 2H ), 2.00 ( d, J = 15Hz, 1H ), 1.71 (dd, J -15, 9.6Hz), 1.60-1.40 ( m, 2H ), 1.30-1.15 ( m, 10H ), 0.81 (t, J = 6.9Hz, 3H ) 实施例 5 (水解氢化)  "HNMR (300Mhz, DMSO) δ 7.18 (d, J = 7.8Hz, 2H), 7.09 (d, J = 7.8Hz, 2H), 4.67 (d, J = 9.6Hz, 1H), 3.65-3.45 (m, 4H), 2.60-2.40 (m, 2H), 2.00 (d, J = 15Hz, 1H), 1.71 (dd, J -15, 9.6Hz), 1.60-1.40 (m, 2H), 1.30-1.15 (m, 10H), 0.81 (t, J = 6.9Hz, 3H) Example 5 (hydrolytic hydrogenation)
2-氨基 -2-[2-(4-辛基苯基)乙基 H, 3-丙二醇  2-amino-2- [2- (4-octylphenyl) ethyl H, 3-propanediol
将 2-乙酰胺基 -2-[2-(4-辛基苯基)- 2-羟基-乙基] -1, 3-丙二醇 ( 1.6 g, 4.38 mmol) 溶于 15 ml甲醇中, 加入 NaOH (0.18 g, 4.5 mmol) , 力口 热回流 2小时后, 将反应液冷却之室温, 滴加浓盐酸 0.4 ml, 使反应液 的 pH值为 5— 6。过滤后将反应液转移至氢化瓶中,加 10% Pd-C( 160 mg) 、 浓盐酸 0.4 ml, 在 20— 40°C的温度下, 于 3 kg/cm2的氢气压力 下震摇 20小时。 反应完全后, 过滤除去催化剂。 添加氢氧化钠进行碱 化, 然后减压浓缩, 残留物用乙酸乙酯提取, 干燥浓縮后得白色固体。 乙酸乙酯重结晶, 得到白色片状晶体 0.94 g, 收率 70%。 Dissolve 2-acetamido-2- [2- (4-octylphenyl) -2-hydroxy-ethyl] -1,3-propanediol (1.6 g, 4.38 mmol) in 15 ml of methanol and add NaOH (0.18 g, 4.5 mmol). After thermal reflux for 2 hours, the reaction solution was cooled to room temperature, and 0.4 ml of concentrated hydrochloric acid was added dropwise to make the pH of the reaction solution 5-6. After filtration, transfer the reaction solution to a hydrogenation flask, add 10% Pd-C (160 mg), 0.4 ml concentrated hydrochloric acid, and shake at 20-40 ° C under a pressure of 3 kg / cm 2 of hydrogen for 20 minutes. hour. After the reaction was completed, the catalyst was removed by filtration. Sodium hydroxide was added for alkalization, and then concentrated under reduced pressure. The residue was extracted with ethyl acetate, dried and concentrated to obtain a white solid. Ethyl acetate was recrystallized to obtain 0.94 g of white flaky crystals in a yield of 70%.
'HNMR (300Mhz, DMSO, D20 exchange) δ 7.07 ( d, J = 9.3Hz, 2H ), 7.03 ( d, J =7·3Ηζ, 2H ), 3.27 ( d, J =10.5Hz, 2H ), 3.22 ( d, J = 10.5Hz, 2H ), 2.55-2.40 ( m, 4H ), 1.55-1.40 ( m, 4H ), 1.30-1.10 ( m, 10H ), 0.80 ( t, J = 6.9Hz, 3H ): EI-MS m/z 308 (M+l), 276 实施例 6 (成盐) 'HNMR (300Mhz, DMSO, D 2 0 exchange) δ 7.07 (d, J = 9.3Hz, 2H), 7.03 (d, J = 7. · 37ζ, 2H), 3.27 (d, J = 10.5Hz, 2H), 3.22 (d, J = 10.5Hz, 2H), 2.55-2.40 (m, 4H), 1.55-1.40 (m, 4H), 1.30-1.10 (m, 10H), 0.80 (t, J = 6.9Hz, 3H) : EI-MS m / z 308 (M + 1), 276 Example 6 (Salt formation)
2-氨基 -2-[2-(4-辛基苯基)乙基] -1, 3-丙二醇盐酸盐  2-amino-2- [2- (4-octylphenyl) ethyl] -1,3-propanediol hydrochloride
将 2-氨基 -2-[2-(4-辛基苯基)乙基] -1, 3-丙二醇 (0.9 g, 2.9 mmol) 加 到 10 ml乙醇中, 不全溶, 滴加浓盐酸饱和的乙醚直至 pH到 4。 减压 浓缩, 粗品用乙醇重结晶, 得到白色片状晶体 0.5 g, 收率 50%。 Add 2-amino-2- [2- (4-octylphenyl) ethyl] -1,3-propanediol (0.9 g, 2.9 mmol) to 10 ml of ethanol. It is not completely soluble. Concentrated hydrochloric acid-saturated solution is added dropwise. Ether until pH reaches 4. stress reliever It was concentrated and the crude product was recrystallized from ethanol to obtain 0.5 g of white flake crystals with a yield of 50%.
'HNMR (300Mhz, DMSO) δ 7.08 ( s, 4H ), 3.49 ( s, 4H ), 2.60-2.40 ( m, 4H ), 1.80-1.70 (m, 2H ), 1.60-1.45 ( m, 2H ), 1.30-1.20 ( m, 10H ), 0.83 ( t, J = 6.6Hz, 3H ) 实施例 7 (先进行氢解) 'HNMR (300Mhz, DMSO) δ 7.08 (s, 4H), 3.49 (s, 4H), 2.60-2.40 (m, 4H), 1.80-1.70 (m, 2H), 1.60-1.45 (m, 2H), 1.30 -1.20 (m, 10H), 0.83 (t, J = 6.6Hz, 3H) Example 7 (Hydrolysis first)
2-乙酰胺基 -2-【2-(4-辛基苯基)乙基 H, 3-丙二酸二乙酯  2-acetamido-2- [2- (4-octylphenyl) ethyl H, 3-ethyl malonate
将实施例 3中制得的 2-乙酰胺基 -2-[2-(4-辛基苯基) -2-氧-乙基] -1, 3- 丙二酸二乙酯 ( 1.76 g, 4.0 mmol) 溶于 30 ml甲醇中, 加入 100 mg 10 % Pd-C、 HC104 (0.8 g, 5.5 mmol) 。 在 30°C、 2 kg/cm2氢压下振摇 16小时, 反应液过滤, 滤液以 NaHC03中和, 减压浓缩, 乙酸乙酯提 取, 无水硫酸钠干燥, 浓縮, 柱层析分离 (石油醚 /乙酸乙酯 3 : 1 ) , 得 l.l g, 收率 63 %。 The 2-acetamido-2- [2- (4-octylphenyl) -2-oxo-ethyl] -1,3-dimalonate (1.76 g, 4.0 mmol) was dissolved in 30 ml of methanol, and 100 mg of 10% Pd-C and HC10 4 (0.8 g, 5.5 mmol) were added. Shake for 16 hours at 30 ° C and 2 kg / cm 2 hydrogen pressure, filter the reaction solution, neutralize the filtrate with NaHC0 3 , concentrate under reduced pressure, extract with ethyl acetate, dry with anhydrous sodium sulfate, concentrate, and column chromatography Separation (petroleum ether / ethyl acetate 3: 1) gave 11 g, yield 63%.
'HNMR (300Mhz, CDC13) δ 7.05 ( 2d, J=8.4Hz, 4Η ), 4.20 ( m, 4H ), 2.69 (m, 2H), 2.55 (t, J = 8.1Hz, 2H), 2.46 ( m, 2H ), 1.95 (s, 3H), 1.58 (m, 2H ), 1.40-1.20 ( m, 16H ), 0.88 ( t, J = 6.6Hz, 3H ) 'HNMR (300Mhz, CDC1 3 ) δ 7.05 (2d, J = 8.4Hz, 4Η), 4.20 (m, 4H), 2.69 (m, 2H), 2.55 (t, J = 8.1Hz, 2H), 2.46 (m , 2H), 1.95 (s, 3H), 1.58 (m, 2H), 1.40-1.20 (m, 16H), 0.88 (t, J = 6.6Hz, 3H)

Claims

权 利 要 求 Rights request
1、 制备以下通式 (I) 之 2-[2-(4-烷基苯基) -乙基 ]-2-氨基-丙二醇的 方法:
Figure imgf000011_0001
式中: R为 C1— 10的烷基;
1. Method for preparing 2- [2- (4-alkylphenyl) -ethyl] -2-amino-propylene glycol of the following general formula (I):
Figure imgf000011_0001
In the formula: R is a C1-10 alkyl group;
所述方法包括以下步骤:  The method includes the following steps:
1)、 烷基苯 (II) 与乙酰氯在 Lewis酸存在下反应, 生成对烷基苯 乙酮 (III) ;  1). Alkylbenzene (II) reacts with acetyl chloride in the presence of Lewis acid to form p-alkylacetophenone (III);
2)、 产物 (III) 在少量 Lewis酸存在下按常规方法形成对垸基 α— 卤代苯乙酮 (IV) ;  2). The product (III) is formed into p-fluorenyl α-haloacetophenone (IV) by a conventional method in the presence of a small amount of Lewis acid;
3)、 产物 (IV) 与 2—酰胺基丙二酸酯 (V) 在碱性条件下缩合形 成 2—酰胺基一 2— [2—对烷基苯基一 2—氧一乙基]丙二酸酯 (VI) ; 3). The product (IV) is condensed with 2-amidomalonate (V) under basic conditions to form 2-amido-2- [2-p-alkylphenyl-2-oxo-ethyl] propane Diester (VI);
4)、 产物 (VI) 还原为 2—酰胺基一 2— [2—对垸基苯基一 2—羟基 —乙基]丙二醇 (VII) ; 4). The product (VI) is reduced to 2-amido-1 2- [2-p-fluorenylphenyl 2-hydroxy-ethyl] propanediol (VII);
5)、 产物 (VII)经水解形成 2—氨基—2— [2—对烷基苯基一 2—羟 基一乙基]丙二醇 (VIII) ; 然后  5), the product (VII) is hydrolyzed to form 2-amino-2- [2-p-alkylphenyl-2-hydroxylethyl] propanediol (VIII); then
6)、 产物 (VIII) 经氢解形成化合物 (I) 。  6). The product (VIII) is hydrolyzed to form the compound (I).
2、 根据权利要求 1的方法, 其中, R为正辛基。 2. The method according to claim 1, wherein R is n-octyl.
3、 根据权利要求 1的方法, 其中, 步骤 4)中所用还原剂为铝或硼 的复氢化物。 3. The method according to claim 1, wherein the reducing agent used in step 4) is aluminum or boron Of the double hydride.
4、根据权利要求 3的方法,其中,所述复氢化物为 LiAlH4、 NaBH4、 KBH4和 LiBH40 4. The method according to claim 3, wherein the double hydride is LiAlH 4 , NaBH 4 , KBH 4 and LiBH 40
5、根据权利要求 1一 4之一的方法, 其中, 步骤 4)中所用的溶剂为 水、 甲醇或乙醇, 且还需硼酸盐或磷酸盐缓冲液参与。 5. The method according to any one of claims 1 to 4, wherein the solvent used in step 4) is water, methanol, or ethanol, and further requires the participation of a borate or a phosphate buffer.
6、 根据权利要求 1的方法, 其中, 步骤 3)中所用的碱为乙醇钠、 甲醇钠、 氢化钠和叔丁醇钾。 6. The method according to claim 1, wherein the base used in step 3) is sodium ethoxide, sodium methoxide, sodium hydride, and potassium tert-butoxide.
7、 根据权利要求 6的方法, 其中, 反应物 IV与 V的摩尔比为 1 : 1 - 1: 2, Na与 IV的比例为 1— 1.5 : 1。 7. The method according to claim 6, wherein the molar ratio of reactants IV to V is 1: 1 to 1: 2, and the ratio of Na to IV is 1 to 1.5: 1.
8、 根据权利要求 1的方法, 其中, 步骤 6)中所用的氢压为 1一 5 kg/cm2 8. The method according to claim 1, wherein the hydrogen pressure used in step 6) is 1 to 5 kg / cm 2
9、 根据权利要求 1的方法, 其中, 产物 (VII) 也可先经氢解、 再 经水解, 最后形成化合物 (I) 。 9. The method according to claim 1, wherein the product (VII) can also be firstly subjected to hydrogenolysis, and then hydrolyzed to finally form the compound (I).
10、 根据权利要求 1的方法, 其中, 产物 (VI) 可先经氢解成 2— 基一 2— [2—对垸基苯基一乙基]丙二酸酯, 然后进行还原和水解。 10. The method according to claim 1, wherein the product (VI) can be firstly hydrogenolyzed to 2-yl-2- [2-p-fluorenylphenylethyl] malonate, followed by reduction and hydrolysis.
11、 式 VI化合物: o ^COOR3 11.Compound of formula VI: o COOR 3
Rr // w ■CH-CH2-C- - NNHHRR22 Rr // wCH-CH 2 -C--NNHHRR 22
、COOR3 VI 其中 1^为 CI— 10的垸基; 为 CI— 4的酰基; R3为 C1— 4的垸基 < , COOR 3 VI where 1 ^ is a fluorenyl group of CI-10; is an acyl group of CI-4; R 3 is a fluorenyl group of C1-4
12、 式 VII化合物: 12.Compounds of formula VII:
OH CH2OH OH CH 2 OH
CH- CH2-C-NHR2 VII CH- CH 2 -C-NHR 2 VII
CH2OH 其中!^是 CI— 10的烷基; R2是 C1— 4的酰基。 CH 2 OH Among them! ^ Is an alkyl group of CI-10; R 2 is an acyl group of C1-4.
13、 根据权利要求 11或 12的化合物, 其中, Rt是正辛基, R2是 乙酰基。 13. The compound according to claim 11 or 12, wherein R t is n-octyl and R 2 is acetyl.
14、 式 VIII化合物: 14. Compound of formula VIII:
OH CH2OH OH CH 2 OH
CH-CH2-C-NH2 CH-CH 2 -C-NH 2
\ VIII  \ VIII
CH2OH 其中 R是 Cl— 10的垸基 < CH 2 OH where R is a fluorenyl group of Cl-10 <
15、 根据权利要求 14的化合物, 其中, R是正辛基。 15. The compound according to claim 14, wherein R is n-octyl.
PCT/CN2000/000046 1999-03-11 2000-03-10 Method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol and intermediates useful in such preparation WO2000053569A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31426/00A AU3142600A (en) 1999-03-11 2000-03-10 Method for preparing 2-2((4-alkylphenyl)-ethyl)-2-amino-propanediol and intermediates useful in such preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB991028791A CN1144779C (en) 1999-03-11 1999-03-11 Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein
CN99102879.1 1999-03-11

Publications (1)

Publication Number Publication Date
WO2000053569A1 true WO2000053569A1 (en) 2000-09-14

Family

ID=5271030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000046 WO2000053569A1 (en) 1999-03-11 2000-03-10 Method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol and intermediates useful in such preparation

Country Status (3)

Country Link
CN (1) CN1144779C (en)
AU (1) AU3142600A (en)
WO (1) WO2000053569A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
US8067396B2 (en) 2002-01-11 2011-11-29 Sankyo Company, Limited Amino alcohol compounds or phosphonic acid derivatives thereof
JP2012508216A (en) * 2008-11-11 2012-04-05 ノバルティス アーゲー Organic compounds
WO2012056458A2 (en) 2010-10-28 2012-05-03 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
WO2014111949A1 (en) 2013-01-21 2014-07-24 Natco Pharma Limited Intermediates and process for the preparation of high purity fingolimod hydrochloride
US8809571B2 (en) 2008-03-19 2014-08-19 Novartis Ag Process for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360124C (en) * 2003-02-25 2008-01-09 杭州华东医药集团生物工程研究所有限公司 Use of 2-amino-2(2-(4-octyl phenyl)ethyl)-1,3-propylene glycol in the preparation of medicaments of preventing and curing immune liver injury
CN1310869C (en) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method
CN102260178A (en) * 2010-05-25 2011-11-30 中国医学科学院药物研究所 Hydroxyl propanediol derivative, its preparation method, its pharmaceutical composition and its purpose
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals
EP2646409A4 (en) * 2010-11-25 2015-12-16 Shilpa Medicare Ltd Fingolimod polymorphs and their processes
EP2658840B1 (en) 2010-12-28 2019-07-03 Synthon BV Process for making fingolimod hydrochloride crystals
CN102120720B (en) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 Novel synthesis method of fingolimod hydrochloride
CN102850319A (en) * 2011-06-27 2013-01-02 中国药科大学 Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) * 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
CN1112786A (en) * 1993-07-23 1995-11-29 药制品公司 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
JPH10147587A (en) * 1996-11-19 1998-06-02 Fujisawa Pharmaceut Co Ltd 2-amino-1,3 propanediol derivative and its pharmaceutical use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) * 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
CN1112786A (en) * 1993-07-23 1995-11-29 药制品公司 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
JPH10147587A (en) * 1996-11-19 1998-06-02 Fujisawa Pharmaceut Co Ltd 2-amino-1,3 propanediol derivative and its pharmaceutical use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA: Chemical Substance Index, Vol. 122, (1995), pages 67CS-68CS *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067396B2 (en) 2002-01-11 2011-11-29 Sankyo Company, Limited Amino alcohol compounds or phosphonic acid derivatives thereof
US8101650B2 (en) 2002-01-11 2012-01-24 Daiichi Sankyo Company, Limited Method for treating a immunology-related disease
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
US8809571B2 (en) 2008-03-19 2014-08-19 Novartis Ag Process for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein
US9133096B2 (en) 2008-03-19 2015-09-15 Novartis Ag Process for the production of 2-amino-2[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein
JP2012508216A (en) * 2008-11-11 2012-04-05 ノバルティス アーゲー Organic compounds
JP2014139179A (en) * 2008-11-11 2014-07-31 Novartis Ag Organic compounds
JP2016028056A (en) * 2008-11-11 2016-02-25 ノバルティス アーゲー Organic compounds
WO2012056458A2 (en) 2010-10-28 2012-05-03 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
US8735627B2 (en) 2010-10-28 2014-05-27 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
WO2014111949A1 (en) 2013-01-21 2014-07-24 Natco Pharma Limited Intermediates and process for the preparation of high purity fingolimod hydrochloride

Also Published As

Publication number Publication date
CN1144779C (en) 2004-04-07
CN1266844A (en) 2000-09-20
AU3142600A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
WO2000053569A1 (en) Method for preparing 2-2[(4-alkylphenyl)-ethyl]-2-amino-propanediol and intermediates useful in such preparation
JP4281248B2 (en) Process for producing quinoline derivative and intermediate
US20020072635A1 (en) Production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols
WO2008035380A2 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
WO2009143684A1 (en) Processes for preparing pemetrexed disodium and its intermediate,4-(4-carbomethoxyphenyl)butanal
JP2012521352A (en) Method for preparing [2- (8,9-dioxo-2,6-diazabicyclo [5.2.0] non-1 (7) -en-2-yl) ethyl] phosphonic acid and its precursors
JP2585462B2 (en) Pyrazolo [1,5-a] pyrimidine derivatives
JP2003535077A (en) Method for producing indole derivative and intermediate of the method
JP4954378B2 (en) Method for preparing 4,5-diaminoshikimic acid derivative
JPH04270285A (en) Pyrazolopryrimidine-based mevalonolactiones
JPH03176485A (en) Coumarin derivative, its preparation and use and thiazolylacetic acid derivative as intermediate
TWI500596B (en) Process for the synthesis of 3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2015012271A1 (en) Method for producing heterocyclic compound
CN100402508C (en) Alkoxytetrazol-1-ylbenzaldehyde compound and process for producing the same
US5519144A (en) Process for the Preparation of Eserethole
JP2769058B2 (en) Preparation of cyclopropane derivatives
US20040010146A1 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
US4533745A (en) Amino ketones and their preparation
JP3144920B2 (en) α-Acylaminoketone derivatives, production method thereof and use thereof
JP3144921B2 (en) Benzyl ester derivative and method for producing the same
JPH07196622A (en) 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole compound, method and intermediate for producing it, and heart circulation drug containing it
JP2593292B2 (en) Intermediate for synthesis of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H, 5H-benzo [i, j] quinolidine-2-carboxylic acid and method for producing the same
JPS63216890A (en) Production of chuanghsinmycin analog
JP2815647B2 (en) Method for producing antiallergic agent intermediate
JPH0521898B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase